Home » Stocks » AUPH

Aurinia Pharmaceuticals Inc. (AUPH)

Stock Price: $14.00 USD 0.00 (0.00%)
Updated Mar 1, 2021 10:45 AM EST - Market open
Market Cap 1.80B
Revenue (ttm) 50.12M
Net Income (ttm) -102.68M
Shares Out 118.47M
EPS (ttm) -0.87
PE Ratio n/a
Forward PE 1,428.57
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $14.00
Previous Close $14.00
Change ($) 0.00
Change (%) 0.00%
Day's Open 14.02
Day's Range 13.89 - 14.37
Day's Volume 1,073,095
52-Week Range 9.83 - 20.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 4 days ago

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the fourth quarter and y...

Benzinga - 6 days ago

Aurinia Pharmaceuticals (NASDAQ:AUPH) announces its next round of earnings this Wednesday, February 24. Here is Benzinga's everything-that-matters guide for this Wednesday's Q4 earnings announ...

Zacks Investment Research - 6 days ago

Aurinia (AUPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Business Wire - 1 week ago

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participa...

Business Wire - 1 week ago

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and year end 2020 fi...

Seeking Alpha - 3 weeks ago

In the following, I review the recent FDA approval and label for LUPKYNIS and tease out some of the bullish implications. I then consider more factors in the comparison to competitor drug Benl...

The Motley Fool - 1 month ago

Approval of a new lupus treatment has investors buzzing around this biotech stock.

The Motley Fool - 1 month ago

The FDA approved the drugmaker's closely watched lupus nephritis therapy.

Benzinga - 1 month ago

AstraZeneca (NASDAQ: AZN) shares are trading higher Monday after the company's CALQUENCE met its primary efficacy endpoint. The German Health Minister also said he expects the EU to approve th...

Other stocks mentioned: AZN, CNST, REGN
Zacks Investment Research - 1 month ago

Aurinia (AUPH) gets approval from the FDA for Lupkynis as a treatment for active lupus nephritis, a disease that causes irreversible kidney damage.

Business Wire - 1 month ago

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that the U.S. Food and Drug Ad...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

Business Wire - 1 month ago

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the management team will participate in two ...

Zacks Investment Research - 2 months ago

Aurinia (AUPH) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Seeking Alpha - 2 months ago

AUPH stock has fallen on two recent developments. I analyze these and argue that the second, a new licensing agreement, is not negative, rather it's a positive for stockholders.

Seeking Alpha - 2 months ago

Aurinia Pharmaceuticals has one of the most important milestones in its history in a few weeks. Next January 22, 2021 is the PDUFA where the FDA will decide the approval of the candidate drug ...

GuruFocus - 2 months ago

Big names like Glaxo, Pfizer and Johnson & Johnson also abandoned promising programs

Other stocks mentioned: UBX
Business Wire - 2 months ago

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collabora...

Business Wire - 2 months ago

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia”) and Lonza Ltd. (SIX: LONN) ("Lonza") today announced they have expanded their ex...

Business Wire - 2 months ago

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced its participation in the Piper Sandler 32nd Annual Virtual H...

Insider Monkey - 3 months ago

In this article we present the list of Top 10 Healthcare Stocks for the Future. Click to skip ahead and see the  Top 5 Healthcare Stocks for the Future .

Other stocks mentioned: INSM, CYTK, NEO, TPTX
Business Wire - 3 months ago

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire - 3 months ago

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate ...

The Motley Fool - 3 months ago

This biotech titan should be a top player on the merger and acquisition scene next year.

Other stocks mentioned: BIIB, HRTX, SAVA
Zacks Investment Research - 3 months ago

Aurinia Pharmaceuticals (AUPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 3 months ago

Aurinia (AUPH) delivered earnings and revenue surprises of -27.27% and -50.85%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 3 months ago

Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) fell 0.15% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 33.33% year over year t...

Business Wire - 3 months ago

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights

Business Wire - 3 months ago

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company, today announced da...

Zacks Investment Research - 3 months ago

Aurinia (AUPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

24/7 Wall Street - 3 months ago

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares slid on Tuesday after the company reported results from its midstage study for the treatment of dry eye syndrome (DES).

Business Wire - 3 months ago

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company, today announce...

Business Wire - 4 months ago

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advan...

Business Wire - 4 months ago

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advan...

Seeking Alpha - 4 months ago

Aurinia's voclosporin demonstrated exceptional Phase 3 trial results to treat Lupus Nephritis “LN”, a significant unmet medical need with blockbuster potential.

Seeking Alpha - 4 months ago

Aurinia: Ready For Voclosporin's Positive Jan. 2021 NDA Announcement, 45% Upside

Business Wire - 4 months ago

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced Time Is Nephrons, the first-ever lupus nephritis ...

Business Wire - 4 months ago

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advan...

Zacks Investment Research - 5 months ago

Aurinia (AUPH) that it has completed the last patient study visit in the AUDREY study evaluating voclosporin ophthalmic solution for the potential treatment of dry eye syndrome.

Business Wire - 5 months ago

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company focused on advancin...

Business Wire - 5 months ago

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate ...

Seeking Alpha - 5 months ago

Voclosporin has proven to be a safer and much more effective derivative of cyclosporin, whose emulsion eye drop formulation was approved by FDA in 2003 to treat DES.

Seeking Alpha - 6 months ago

Aurinia Pharmaceuticals, Inc.'s (AUPH) CEO Peter Greenleaf on Q2 2020 Results - Earnings Call Transcript

Benzinga - 6 months ago

Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) were unchanged after-market trading after the company reported Q2 results.

Zacks Investment Research - 6 months ago

Aurinia (AUPH) delivered earnings and revenue surprises of -13.04% and -53.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 6 months ago

VICTORIA, British Columbia--(BUSINESS WIRE)--AURINIA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS

Zacks Investment Research - 6 months ago

Let us take a look at two small biotech companies, VIR and AUPH, which are gearing up for their earnings release.

Other stocks mentioned: VIR
Seeking Alpha - 6 months ago

Aurinia Pharmaceuticals Is A Long-Term Buy With Near-Term Catalysts

Zacks Investment Research - 6 months ago

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 6 months ago

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer ...

About AUPH

Aurinia Pharmaceuticals, a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.

Industry
Biotechnology
IPO Date
Jan 26, 1999
CEO
Peter Greenleaf
Stock Exchange
NASDAQ
Ticker Symbol
AUPH
Full Company Profile

Financial Performance

In 2020, AUPH's revenue was $50.12 million, an increase of 15,660.38% compared to the previous year's $318,000. Losses were -$102.68 million, 16.2% more than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for AUPH stock is "Strong Buy." The 12-month stock price forecast is 11.50, which is a decrease of -17.86% from the latest price.

Price Target
$11.50
(-17.86% downside)
Analyst Consensus: Strong Buy